Genetix Pharmaceuticals, Inc. Appoints President of U.S. Operations
In this newly-created position, Mr Williamson is responsible for leading Genetix' commercial operations, servicing clients within the life sciences and diagnostics part of the business and increasing the Company's focus on the U.S. marketplace. In addition to his commercial leadership responsibilities, Mr Williamson will also serve as Genetix' Global Leader of Diagnostic Business Development, responsible for establishing and executing the Company's growth strategy in the diagnostic and biomarker imaging markets.
Mr Williamson has over 20 years of experience developing businesses within the bioscience technology marketplace. As president of Biacore, Inc., the publicly-held analytical instrument company, he helped to drive company growth and also facilitated the post-acquisition integration with GE Healthcare Life Sciences. Prior to Biacore, Mr Williamson was President of Pyrosequencing, Inc., a European-owned public genomics company. Mr Williamson has also held commercial management positions at Genzyme Genetics and Roche Laboratories.
Terry Pizzie, Director of Global Commercial Operations, commented:
"With his broad-ranging expertise in life sciences and diagnostic technology, Jerry will be a tremendous asset to the Genetix team. His strong track record and experience in driving growth for international companies will be invaluable as we continue to build our presence in the U.S. and significantly grow our business on a global scale."
Enquiries:
Genetix Group plc Mark Reid, Chief Executive Tel: +44 (0) 1425 624600 Andrew Kellett, Finance Director
Financial Dynamics Deborah Scott/Lara Mott Tel: +44 (0) 20 7831 3113 Piper Jaffray Ltd. James Steel Tel: +44 (0) 20 3142 8700
Notes to Editors:
About Genetix
Based in New Milton, UK, Genetix delivers the competitive edge in cell identification and selection from discovery to diagnosis. Genetix' technologies are bringing new efficiencies to biotherapeutic and biomarker research from target discovery through to clinical diagnosis. The Company continually delivers technological breakthroughs to increase its customers' productivity and success.
Genetix' customer base includes many of the world's leading biopharmaceutical, cytogenetic and cancer pathology groups. The Company's achievements helped revolutionise cell biology, proteomics and genomics. Genetix made a significant contribution to the Human Genome Project by supplying high-throughput equipment to seven of the leading eight laboratories of the consortium. Today, through its R&D expertise and scientific resource, Genetix is committed to the continual development of innovative solutions to accelerate the rate of cell based research.
For more information please visit www.genetix.com